share_log

Windtree Announces Partnership With New Growth Advisors To Leverage Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic Transaction

Windtree Announces Partnership With New Growth Advisors To Leverage Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic Transaction

Windtree宣布与新成长顾问建立合作关系,以利用第二阶段Istaroxime研究在心源性休克中的潜在战略交易。
Benzinga ·  12/04 21:13

Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that it has engaged New Growth Advisors ("NGA"), a leading life sciences consulting firm chosen by companies seeking discreet, conflict-free, and knowledgeable advice on complex M&A, asset sale, research, capital markets, and licensing transactions, as its strategic advisor to lead a process in respect of Windtree's cardiovascular portfolio, including a potential out-licensing transaction or asset sale. NGA has advised on transactions with an aggregate value approaching $400 million from 2023 through 2024.

windtree therapeutics公司("windtree"或"公司")(纳斯达克CM:WINT),一家专注于推进早期和晚期创新疗法以治疗关键疾病和疾病的生物技术公司,今天宣布,已聘请新兴增长顾问公司("NGA"),这是一家领先的生命科学咨询公司,为寻求在复杂的并购、资产出售、研究、资本市场和许可交易上寻求慎重、无冲突和知识渊博的建议的公司选择的战略顾问,带领进行windtree心血管组合品的流程,包括潜在的外部许可交易或资产出售。 NGA已经就一项价值接近40000万美元的交易提供建议,时间从2023年到2024年。

The Company seeks to leverage the positive early cardiogenic shock and acute heart failure results (including the recent positive Phase 2b in early cardiogenic shock) to better address the breadth of opportunities and secure potentially non-dilutive funding via a partnership for istaroxime as well as the next generation, oral SERCA2a activators for all global territory ex-Greater China. NGA has been engaged to manage the current inbound interest as well as to run an expanded out-licensing process.

公司试图利用早期心原性休克和急性心力衰竭的积极结果(包括最近在早期心原性休克中的积极2期结果)来更好地应对各种机会,并通过与全球(大中华以外)的伙伴关系以及下一代口服SERCA2a激活剂为istaroxime以及全球领土获得潜在的非摊薄资金。 NGA已受托管理当前的入境兴趣,并扩大外部许可流程。

The Company currently has a licensing agreement for the Greater China territory for istaroxime, dual mechanism SERCA2a activators and rostafuroxin with Lee's Pharmaceuticals (HK) Limited ("Lee's") for which it may receive up to $138 million in potential milestones and low double-digit royalties. Lee's pays for all development costs and is working with Windtree on the planning, Lee's expects to start Phase 3 in acute heart failure in its licensed territory in the first half of 2025.

公司目前已经与李氏制药(香港)有限公司(以下简称"李氏")签订了istaroxime、双机制SERCA2a激活剂和rostafuroxin在大中华领土的许可协议,根据该协议,公司可能获得高达13800万美元的潜在里程碑以及低两位数的特许权使用费。 李氏支付所有开发成本,并与windtree合作规划,李氏预计将于2025年上半年在许可领土内启动急性心力衰竭的3期研究。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发